Wolverine Trading
BCLI

Wolverine Trading’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Wolverine Trading’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,793
Closed -$83.8K – 4494
2023
Q2 		$83.8K Buy
2,793
+1,000
+56% +$41.4K ﹤0.01% 3825
2023
Q1 		$67K Sell
1,793
-120
-6% -$3.48K ﹤0.01% 3764
2022
Q4 		$47K Sell
1,913
-1,974
-51% -$73.8K ﹤0.01% 3593
2022
Q3 		$243K Buy
+3,887
New +$195K ﹤0.01% 3371
2022
Q2 		– Sell
-733
Closed -$37K – 4503
2022
Q1 		$37K Buy
+733
New +$36K ﹤0.01% 5149
2021
Q2 		– Sell
-1,593
Closed -$89K – 5967
2021
Q1 		$89K Sell
1,593
-127
-7% -$9.59K ﹤0.01% 5479
2020
Q4 		$119K Buy
+1,720
New +$234K ﹤0.01% 4414
2017
Q4 		– Sell
-720
Closed -$44K – 4893
2017
Q3 		$44K Buy
+720
New +$46.6K ﹤0.01% 4247

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Wolverine Trading's BCLI Position: Q3 2023 in Review

Wolverine Trading sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 897 shares — an estimated $26.9K sold.

Wolverine Trading first reported a position in BCLI in Q1 2019 and held it in 7 quarters. The position peaked at $190K in Q2 2019. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Wolverine Trading reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Wolverine Trading sold 897 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $26.9K.
  • Wolverine Trading first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2019 and held it in 7 quarters.
  • Wolverine Trading's BRAINSTORM CELL THERAPUTC position peaked at $190K in Q2 2019.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Wolverine Trading's 13F filing for Q3 2023, filed 15 Nov 2023.